CF PHARMTECH (02652) has announced that its inhalation drug production facility located in Suzhou, China, has successfully passed an on-site Good Manufacturing Practice (GMP) compliance inspection conducted by a regulatory authority from a member state of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

The inspection covered the site's production management and quality control systems, premises, facilities, equipment, data integrity, and computerized systems.

Passing this inspection confirms that the facility's quality management system and production capabilities meet PIC/S GMP standards, opening a significant market access pathway for the company's inhalation products.

The targeted markets have populations in the hundreds of millions and bear a heavy burden of chronic respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), yet the accessibility of inhalation therapies in these regions remains below the international average.

The group had previously obtained China GMP certification and passed an audit by a European Union Qualified Person (QP).

This latest successful inspection by a PIC/S member state marks another milestone in the company's global expansion and supports its strategy of supplying high-quality, cost-effective inhalation products and respiratory disease solutions to overseas markets.